Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo's portfolio shake-up progressing well, says Citi

(Sharecast News) - Citi has renewed its coverage of Anglo American with a 'neutral' rating, saying that the mining giant's portfolio restructuring is progressing well but appears priced into the stock. Nevertheless, the bank sees some upside with a target price of 2,600p, compared with Monday's closing price of 2,257.5p, despite a decent performance over the past year as the company continues to "optimise" its business through demergers and disposals of certain divisions.

"AAL has made decent progress on its portfolio optimization with coal and nickel business disposals already sealed, while PGM demerger is on track. Diamond remains the last piece in the pack of non-core assets," Citi said in a research note.

"This marked shift in the investment case has led to a c30% share price outperformance since the announcement in May'24, implying a sharp re-rating of the remainco business."

The stock's current valuation puts it trading at 6.1 times 2025 estimated EBITDA, which is a premium to others in the diversified mining sector.

However, further upside could be seen in a potential rally in commodity prices or renewed M&A interest from global peers, Citi said.

Shares were up 1.3% at 2,285.5p by 1136 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.